About Eclipsebio
The Integrated Platform for RNA Drug Development
Eclipsebio is an RNA drug enablement company that combines AI-powered sequence design, rapid prototyping, and sequencing-based analytics into a single integrated platform called eCOMPASS. Founded in 2017 in San Diego by RNA biologists and drug developers, we have partnered with over 100 pharmaceutical and biotechnology organizations, including 80% of the top 30 global pharma companies, to de-risk RNA drug development from first design through regulatory filing.
Drug development enabled by RNA biology
With our unique collection of proprietary next-generation sequencing assays and AI models, we provide actionable insights that are unavailable from any other technology or solutions provider. Our mission is to provide biopharma and biotechs with data-driven support for effective drug discovery and development, not black box predictions or incomplete data from antiquated assays. Our approach is supported by over 30+ peer-reviewed publications and used by 80% of the top 30 global biopharma.
AI-powered RNA design built by RNA biologists on 500,000+ proprietary data points
Sequencing-based analytics at nucleotide resolution for comprehensive quality control
Integrated design-make-test workflow for designed and validated therapies
Learn more
about Eclipsebio
Meet our leadership team
Our team of RNA experts is skilled in solving the major challenges for drug development and research. Learn more about our leadership and advisory board here.
Catch up on our latest news
At Eclipsebio we are continuously innovating to provide groundbreaking insights for our partners. Learn about the latest updates on our capabilities and other developments here.
Explore our events
Our team of RNA experts is frequently presenting about our cutting-edge solutions at conferences and webinars. Discover where we will be next.
Join our team
Are you passionate about the power of RNA-based therapeutics to treat previously untreatable diseases? Join our team today to help our partners succeed in creating the next generation of RNA medicines.